Best GLP-1 Providers in Louisiana (2026)

See by medication

Looking for a specific GLP-1? Browse Louisiana providers by drug.

About GLP-1s in Louisiana

Louisiana allows telehealth GLP-1 prescribing. Louisiana Medicaid (Healthy Louisiana) covers GLP-1s only for type 2 diabetes.

• •Louisiana has the 5th-highest adult obesity rate in the US at 38.6%
• •Louisiana Medicaid restricts GLP-1 coverage to diabetes
• •Compounded semaglutide is widely available through telehealth

Top Cities for GLP-1 Treatment in Louisiana

Telehealth providers ship to all Louisiana addresses, but demand is highest in these metro areas:

Prefer an in-person clinic? Browse the Louisiana GLP-1 clinic directory →

GLP-1 Care Access in Louisiana: The Numbers

Louisiana has 391 NPI-registered in-person weight-management clinics across 59 cities — 7 with an obesity-medicine taxonomy, 144 endocrinology, and 245 bariatric — alongside 88 telehealth programs that ship to Louisiana addresses. The cheapest verified ongoing compounded semaglutide price available to Louisiana residents is $79/mo (tirzepatide: $97/mo). Full methodology and the 50-state table: GLP-1 care access by state.

Insurance & Medicaid in Louisiana

In Q1 2026, Louisiana Medicaid reimbursed approximately $44,587,259 across 42,700 GLP-1 prescriptions (all covered indications, gross before rebates — federal SDUD data; full state series here).

Most insurance plans in Louisiana cover GLP-1s for type 2 diabetes (Ozempic, Mounjaro), but coverage for obesity-only indications (Wegovy, Zepbound) is much more limited and often requires prior authorization. If your insurance won't cover brand-name GLP-1s, compounded semaglutide through telehealth is typically the most affordable option at around $195/mo.

For the exact criteria, drug list, and appeal process, read our Louisiana Medicaid GLP-1 coverage & prior-authorization guide. For coverage backdoors, Zepbound is FDA-approved for obstructive sleep apnea, and Wegovy for kidney and cardiovascular indications, which some plans cover even when they exclude weight-loss-only use.

Obesity in Louisiana

According to CDC data, 38.6% of Louisiana adults have obesity (BMI of 30 or higher). This places Louisiana at #5 out of 50 states. Access to GLP-1 medications like semaglutide and tirzepatide has expanded significantly through telehealth, helping Louisiana residents get clinically supervised weight loss treatment from home.

To choose a medication, compare the clinical-trial results behind each drug, see our best semaglutide and tirzepatide provider rankings, or track the next-generation GLP-1 pipeline.

Frequently Asked Questions